We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys During Liver Transplant by Measuring Some Physiological Substances in Blood and Urines

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2014 by Dr. Paolo Feltracco, Azienda Ospedaliera di Padova.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01650116
First Posted: July 26, 2012
Last Update Posted: November 20, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Paolo Feltracco, Azienda Ospedaliera di Padova
  Purpose
The purpose of this study is to verify any existing relationship between urinary parameters (such as excretion of sodium, chlorine, urinary partial CO2 pressure [PuCO2]) and general volemic indicators (such as PiCCO, ScvO2, O2 delivery) during liver transplant.

Condition
Hypovolemia During Liver Transplantation Renal Hypoperfusion During Liver Transplantation

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Evaluation of Sodium Urinary Excretion, Chlorine Urinary Excretion, Urinary Partial CO2 Pressure as Renal Perfusion Indicators During Liver Transplant. Comparison With Other Polemic State Indicators (Such as PiCCO, ScvO2, O2 Delivery).

Resource links provided by NLM:


Further study details as provided by Dr. Paolo Feltracco, Azienda Ospedaliera di Padova:

Primary Outcome Measures:
  • Determination of hemodynamic indicators (PiCCO, ScvO2, O2-delivery) and three urinary analytes (sodium, chloride, CO2 partial pressure) [ Time Frame: During the stay of the patient in the operating room (in average 8 hours) and the subsequent stay in the post-surgery intensive care unit (in average 5 days) ]

Estimated Enrollment: 50
Study Start Date: July 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing liver transplantation
Criteria

Inclusion Criteria:

  • surgery for liver transplantation
  • age 18-75
  • ASA class I-III

Exclusion Criteria:

  • age above 75 or under 18
  • ASA class IV
  • pre-existing renal failure
  • pregnant patients
  • patients unable to give written consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01650116


Contacts
Contact: Paolo Feltracco, M.D. +393493410225 paolofeltracco@inwind.it
Contact: Andrea Bortolato, M.D. +393316169933 freeandrea.b@libero.it

Locations
Italy
Azienda Ospedaliera di Padova Recruiting
Padova, Italy, 35128
Contact    +390498218285      
Contact    +390498218286      
Principal Investigator: Paolo Feltracco, M.D.         
Principal Investigator: Andrea Bortolato, M.D.         
Sub-Investigator: Daniele Bonvicini, M.D.         
Sub-Investigator: Tommaso Tonetti, M.D.         
Sponsors and Collaborators
Azienda Ospedaliera di Padova
Investigators
Study Chair: Carlo Ori, Prof. M.D. Università degli Studi di Padova - Azienda Ospedaliera di Padova
Principal Investigator: Paolo Feltracco, M.D. Azienda Ospedaliera di Padova
Principal Investigator: Andrea Bortolato, M.D. Azienda Ospedaliera di Padova
  More Information

Responsible Party: Dr. Paolo Feltracco, Principal Investigator, Azienda Ospedaliera di Padova
ClinicalTrials.gov Identifier: NCT01650116     History of Changes
Other Study ID Numbers: 2661P
First Submitted: July 24, 2012
First Posted: July 26, 2012
Last Update Posted: November 20, 2014
Last Verified: November 2014

Keywords provided by Dr. Paolo Feltracco, Azienda Ospedaliera di Padova:
hypovolemia
renal hypoperfusion
liver transplantation
sodium
chloride
PuCO2
ScvO2
PiCCO
O2-delivery
hemodynamic indexes

Additional relevant MeSH terms:
Hypovolemia
Pathologic Processes